Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q02556
UPID:
IRF8_HUMAN
Alternative names:
Interferon consensus sequence-binding protein
Alternative UPACC:
Q02556; A0AV82
Background:
Interferon regulatory factor 8 (IRF8), also known as Interferon consensus sequence-binding protein, plays a pivotal role in immune response regulation. It binds specifically to the regulatory regions of type I interferon and MHC class I genes, influencing transcription. IRF8's involvement extends to dendritic cell differentiation, macroautophagy in dendritic cells, and repressing osteoclast differentiation.
Therapeutic significance:
IRF8's critical role in immune system regulation and its direct association with Immunodeficiency 32A and 32B, diseases characterized by susceptibility to infections and immunodeficiency, underscores its potential as a target for therapeutic intervention. Understanding IRF8's mechanisms could lead to novel treatments for these immunodeficiencies.